GPR34 inhibition reprograms tumor-associated macrophages and enhances the sensitivity of anti-PD-1 therapy in hepatocellular carcinoma
GPR34 is pivotal in driving macrophage M2 polarization, and inhibitor targeting GPR34 represents promising antitumor agent capable of augmenting the efficacy of anti-PD-1 therapy.
Authors
- Xinyi Liu (ORCID: https://orcid.org/0000-0002-9347-8657)
- Feng Zhang (ORCID: https://orcid.org/0000-0002-3214-9286)
- Wenfeng Liu (ORCID: https://orcid.org/0000-0003-4734-9771)
- Qiang Yu (ORCID: https://orcid.org/0000-0003-2132-8278)
- Wenqing Tang
- Qiuyu Jiang (ORCID: https://orcid.org/0000-0003-4461-2829)
- Ling Dong
Institutions
- Fudan University (CN)
- Zhongshan Hospital (CN)
- Shanghai Institute of Hematology (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1186/s12935-025-04030-3
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China